Cargando…
Review of mifamurtide in the treatment of patients with osteosarcoma
Osteosarcoma is the most common primary malignant tumor of bone. The disease, however, is very rare with less than 2,000 expected patients at all age groups per year within the European Union and the United States of America. With multimodal therapy, which combines multiagent chemotherapy and comple...
Autores principales: | Kager, Leo, Pötschger, Ulrike, Bielack, Stefan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893760/ https://www.ncbi.nlm.nih.gov/pubmed/20596505 |
Ejemplares similares
-
Blockade of IL-10 Signaling Ensures Mifamurtide Efficacy in Metastatic Osteosarcoma
por: Nastasi, Nicoletta, et al.
Publicado: (2023) -
Advances in the management of osteosarcoma
por: Bielack, Stefan S., et al.
Publicado: (2016) -
Current Insights into the Management of Late Chemotherapy Toxicities in Pediatric Osteosarcoma Patients
por: Hecker-Nolting, Stefanie, et al.
Publicado: (2021) -
Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells
por: Punzo, Francesca, et al.
Publicado: (2020) -
Improved osteosarcoma survival with addition of mifamurtide to conventional chemotherapy – Observational prospective single institution analysis
por: Múdry, Peter, et al.
Publicado: (2021)